Evidence map›Paper›PMID 29969701›Full record

ArticleJournal of the American Academy of Dermatology2018

Natural history of disease activity and damage in patients with cutaneous lupus erythematosus.

Khor Jia Ker, Noelle M Teske, Rui Feng, Benjamin F Chong, Victoria P Werth

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Academy of Dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Khor Jia KerNational Skin Centre, Singapore, Singapore; Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania.
Noelle M TeskeDepartment of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas.
Rui FengDepartment of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania.
Benjamin F ChongDepartment of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: ben.chong@utsouthwestern.edu.
Victoria P WerthDepartment of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania; Medical Research, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania. Electronic address: werth@mail.med.upenn.edu.
The University of Texas Southwestern Medical Center · USNational Skin Centre · SGPhiladelphia VA Medical Center · USUniversity of Pennsylvania · US

Funding

PATIENT-ORIENTED RESEARCH IN SKIN AUTOMMUNE DISEASEK24AR002207 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI WERTH, VICTORIA P · 2001 to 2012
$1.3M
Molecular Markers in Discoid Lupus ErythematousK23AR061441 · NIAMS · UT SOUTHWESTERN MEDICAL CENTER · PI CHONG, BENJAMIN FRANKLIN · 2012 to 2016
$653k
NIAMS NIH HHS K23 AR061441NIAMS NIH HHS K24 AR002207
6 · The paper itself

Abstract

backgroundLong-term studies characterizing disease course of cutaneous lupus erythematosus (CLE) patients on standard-of-care treatments are lacking.

objectiveWe characterized and compared disease course of CLE patients using Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI).

methodsIn total, 83 CLE patients with CLASI scores collected from ≥3 study visits within 2 years had disease activity and damage trends calculated by average change scores (ACS). Trends were classified as improved (ACS ≤-3), worsened (ACS ≥3), or stable (-3 < ACS < 3). Linear regression models compared CLASI trends between groups.

resultsMost patients (72.73%) with initial CLASI activity (CLASI-A) scores >9 (N = 33) had improved disease activity versus 14.00% of those with initial CLASI-A scores ≤9 (N = 50). Linear regression analyses showed significant improvement in CLASI-A scores in patients of minority races (P < .05), with baseline CLASI-A scores >9 (P < .0001), baseline CLASI damage (CLASI-D) scores ≥10 (P = .0001), and CLE disease duration ≤1 year (P = .01). Of 28 patients with baseline CLASI-D scores ≥10, 35.71% had improvements in damage, while 5.26% of patients with initial CLASI-D scores of 5-9 (N = 19) and 0% with initial CLASI-D scores <5 (N = 36) (P = .0005) had improvements. LIMITATIONS: Limitations include small sample size.

conclusionBaseline CLASI-A score >9, minority race, and short disease duration predict CLE disease activity improvement. A baseline CLASI-D score ≥10 is associated with disease damage improvement.

Indexed as

AdultAge of OnsetAnti-Inflammatory AgentsAntimalarialsDisease ProgressionFemaleHumansImmunosuppressive AgentsLinear ModelsLupus Erythematosus, CutaneousMaleMiddle AgedProspective StudiesSeverity of Illness IndexSkinSmokingAnti-Inflammatory AgentsAntimalarialsImmunosuppressive AgentsCutaneous Lupus Disease Area and Severity Indexcutaneous lupus erythematosusdisease activitydisease damagelongitudinal

Identifiers

PMID29969701
PMCPMC6234101
OpenAlexW2811015345

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.